Pharsight

1. Camzyos patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9181200	BRISTOL	Pyrimidinedione compounds	Jun, 2034 (10 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883	BRISTOL	Pyrimidinedione compounds	Jun, 2034 (10 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 28, 2029
New Chemical Entity Exclusivity (NCE)	Apr 28, 2027
M (M)	Jun 15, 2026

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: 2026-04-28

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
2.5MG	CAPSULE;ORAL	Prescription
5MG	CAPSULE;ORAL	Prescription
10MG	CAPSULE;ORAL	Prescription
15MG	CAPSULE;ORAL	Prescription

CAMZYOS family patents

2. Onureg patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP20201105A	2023-04-06	STADA Arzneimittel AG	Granted and Under Opposition
EP20201105A	2023-04-04	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP20201105A	2023-03-31	SANDOZ AG	Granted and Under Opposition
EP20201105A	2023-03-31	Synthon BV	Granted and Under Opposition
EP20201105A	2023-03-31	Hamm&Wittkopp Patentanwälte PartmbB	Granted and Under Opposition
EP19213148A	2022-05-11	STADA Arzneimittel AG	Granted and Under Opposition
EP19213148A	2022-05-11	Generics [UK] Limited	Granted and Under Opposition
EP19213148A	2022-05-10	TEVA PHARMACEUTICAL INDUSTRIES, LTD.	Granted and Under Opposition
EP19213148A	2022-05-10	Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB	Granted and Under Opposition
EP19213148A	2022-05-09	SANDOZ AG	Granted and Under Opposition
EP19213148A	2022-04-29	Lotus Pharmaceutical Co., Ltd.	Granted and Under Opposition
EP13182721A	2020-09-11	SANDOZ AG	Granted and Under Opposition
EP13182721A	2020-09-10	Hoffmann Eitle	Granted and Under Opposition
EP13182721A	2020-09-04	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP13182721A	2020-08-30	Generics (U.K.) Limited	Granted and Under Opposition
EP09746975A	2019-08-28	Generics (UK) Ltd	Granted and Under Opposition
EP09746975A	2019-08-27	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571436	BRISTOL	NA	May, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Sep 1, 2023
Orphan Drug Exclusivity (ODE)	Sep 1, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg and 300 mg	30 Sep, 2021	1		03 Jun, 2030

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

ONUREG family patents

3. Sotyktu patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47929	BRISTOL	Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses	Nov, 2033 (10 years from now)
US10000480	BRISTOL	Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses	Nov, 2033 (10 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021475	BRISTOL	Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses	Nov, 2033 (10 years from now)